CARISMA THERAPEUTICS INC (CARM) Stock News
NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD
CARM Latest News, Press Releases and Analysis
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Curious about the stocks that are showing activity after the closing bell on Wednesday?
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for...
Carisma Therapeutics Announces Changes to its Board of Directors
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Present at Upcoming Conferences
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q2 2024
CARM stock results show that CARISMA Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CARISMA Therapeutics (NASDAQ:CARM) just reported results for the second quarter...
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024
CARM stock results show that CARISMA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CARISMA Therapeutics (NASDAQ:CARM) just reported results for the first quarter ...
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023
CARM stock results show that CARISMA Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
FDA clears IND application for Carisma cellular therapy (NASDAQ:CARM)
Carisma Therapeutics gains 14% premarket as FDA approves IND application for novel cellular therapy to treat solid tumors overexpressing HER2.
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
If you can handle the stomach-churning volatility and know when to call it quits, these top stocks under $5 could be intriguing.
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...